Mendes, GabrielSantos, Maria LeonorRamalho, João FranciscoBruschy-Fonseca, AnaLito, LuísPedro, DiogoDuarte, AidaCristino, José MeloCaneiras, Catia2023-12-072023-12-072023Int J Antimicrob Agents. 2023 Dec;62(6):1070130924-8579http://hdl.handle.net/10451/61161© 2023 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.Ceftazidime/avibactam (CZA) is a novel drug that inactivates Ambler class A, including Klebsiella pneumoniae carbapenemases (KPC), class C and class D β-lactamases, but is not active against metallo-β-lactamases (class B). Despite its limited use worldwide, emerging cases of CZA-resistant isolates producing variants of the blaKPC gene have been reported. In this study, we report a novel KPC-98 variant conferring CZA resistance identified in a highly virulent and multidrug-resistant clinical isolate of K. pneumoniae, belonging to the high-risk international clone sequence type 13 (ST13).engjournal article10.1016/j.ijantimicag.2023.1070131872-7913